Kinase News

Kinase News http://kinasecentral.wordpress.com News on Kinase Inhibitors for the Pharma Industry Tue, 28 Oct 2008 18:32:28 +0000 en hourly 1 http://wordpress.com/ http://s2.wp.com/i/buttonw-com.png Kinase News http://kinasecentral.wordpress.com Please update your bookmarks http://kinasecentral.wordpress.com/2008/10/28/please-update-your-bookmarks/ http://kinasecentral.wordpress.com/2008/10/28/please-update-your-bookmarks/#comments Tue, 28 Oct 2008 16:27:19 +0000 crimsoncanary http://kinasecentral.wordpress.com/?p=809 ]]> Kinase News is no longer being updated here, but is instead at http://www.kinasecentral.com

Please update your bookmarks! Archived news is also present on the new site.

]]> http://kinasecentral.wordpress.com/2008/10/28/please-update-your-bookmarks/feed/ 0 crimsoncanary Nervianos Aurora kinase effective and safe in Phase I http://kinasecentral.wordpress.com/2008/10/23/nervianos-aurora-kinase-effective-and-safe-in-phase-i/ http://kinasecentral.wordpress.com/2008/10/23/nervianos-aurora-kinase-effective-and-safe-in-phase-i/#comments Thu, 23 Oct 2008 18:35:07 +0000 crimsoncanary http://kinasecentral.wordpress.com/?p=802 ]]> Data presented at the EORTC-NCI-AACR Symposium show Nerviano’s Aurora kinase inhibitor PHA 739358 to demonstrate good tolerability early signs of efficacy

]]> http://kinasecentral.wordpress.com/2008/10/23/nervianos-aurora-kinase-effective-and-safe-in-phase-i/feed/ 0 crimsoncanary GlaxoSmithKline chooses not to exercise right to MET/RET/VEGFR2 inhibitor XL184 http://kinasecentral.wordpress.com/2008/10/23/glaxosmithkline-does-not-exercise-right-to-metretvegfr2-inhibitor-xl184/ http://kinasecentral.wordpress.com/2008/10/23/glaxosmithkline-does-not-exercise-right-to-metretvegfr2-inhibitor-xl184/#comments Thu, 23 Oct 2008 18:18:52 +0000 crimsoncanary http://kinasecentral.wordpress.com/?p=799 ]]> GlaxoSmithKline has decided not to exercise its option to license MET/RET/VEGFR2 inhibitor from Exelixis

]]> http://kinasecentral.wordpress.com/2008/10/23/glaxosmithkline-does-not-exercise-right-to-metretvegfr2-inhibitor-xl184/feed/ 0 crimsoncanary Exelixis PI3K Inhibitor XL147 effective in Phase I http://kinasecentral.wordpress.com/2008/10/23/exelixis-pi3k-inhibitor-xl147-effective-in-phase-i/ http://kinasecentral.wordpress.com/2008/10/23/exelixis-pi3k-inhibitor-xl147-effective-in-phase-i/#comments Thu, 23 Oct 2008 18:09:25 +0000 crimsoncanary http://kinasecentral.wordpress.com/?p=796 ]]> Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K inhibitor XL147 to exhibit ‘robust pharmacodynamics’ and preliminary clinical benefit

]]> http://kinasecentral.wordpress.com/2008/10/23/exelixis-pi3k-inhibitor-xl147-effective-in-phase-i/feed/ 0 crimsoncanary Exelixis PI3K/mTOR Inhibitor XL765 effective in Phase I http://kinasecentral.wordpress.com/2008/10/23/exelixis-pi3kmtor-inhibitor-xl765-effective-in-phase-i/ http://kinasecentral.wordpress.com/2008/10/23/exelixis-pi3kmtor-inhibitor-xl765-effective-in-phase-i/#comments Thu, 23 Oct 2008 18:04:25 +0000 crimsoncanary http://kinasecentral.wordpress.com/?p=788 ]]> Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K/mTOR kinase inhbitor XL765 to show demonstrate ‘robust pharmacodymanics’

]]> http://kinasecentral.wordpress.com/2008/10/23/exelixis-pi3kmtor-inhibitor-xl765-effective-in-phase-i/feed/ 0 crimsoncanary Exelixis Raf kinase inhibitor XL281 effective in Phase I http://kinasecentral.wordpress.com/2008/10/23/exelixis-xl281-effective-in-phase-i/ http://kinasecentral.wordpress.com/2008/10/23/exelixis-xl281-effective-in-phase-i/#comments Thu, 23 Oct 2008 18:01:30 +0000 crimsoncanary http://kinasecentral.wordpress.com/?p=786 ]]> Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis RAF kinase inhbitor XL281 to show early signs of clinical activity

]]> http://kinasecentral.wordpress.com/2008/10/23/exelixis-xl281-effective-in-phase-i/feed/ 0 crimsoncanary Exelixis IGF-1R/Src inhibitor XL228 effective in Phase I http://kinasecentral.wordpress.com/2008/10/23/exelixis-xl228-effective-in-phase-i/ http://kinasecentral.wordpress.com/2008/10/23/exelixis-xl228-effective-in-phase-i/#comments Thu, 23 Oct 2008 17:58:49 +0000 crimsoncanary http://kinasecentral.wordpress.com/?p=782 ]]> Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis’ IGF-1R/Src inhibitor XL228 to show signs of Clinical Benefit inpatients with advanced malignancies

]]> http://kinasecentral.wordpress.com/2008/10/23/exelixis-xl228-effective-in-phase-i/feed/ 0 crimsoncanary Exelixis MET/VEGFR2/RET inhibitor XL184 effective in Phase I http://kinasecentral.wordpress.com/2008/10/23/exelixis-xl184-effective-in-phase-i/ http://kinasecentral.wordpress.com/2008/10/23/exelixis-xl184-effective-in-phase-i/#comments Thu, 23 Oct 2008 17:55:18 +0000 crimsoncanary http://kinasecentral.wordpress.com/?p=780 ]]> Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis MET/VEGFR2/RET inhbitor XL184 demonstrates a 55% Response Rate and 84% Disease Control Rate in Patients with Medullary Thyroid Cancer

]]> http://kinasecentral.wordpress.com/2008/10/23/exelixis-xl184-effective-in-phase-i/feed/ 0 crimsoncanary Millennium present data on kinase programs at EORTC-NCI-AACR meeting http://kinasecentral.wordpress.com/2008/10/23/millennium-present-data-on-kinase-programs-at-eortc-nci-aacr-meeting/ http://kinasecentral.wordpress.com/2008/10/23/millennium-present-data-on-kinase-programs-at-eortc-nci-aacr-meeting/#comments Thu, 23 Oct 2008 17:48:43 +0000 crimsoncanary http://kinasecentral.wordpress.com/?p=776 ]]> Data presented at the EORTC NCI AACR meeting detail data and progress on Millennium kinase programs:

MLN8237 – Aurora A – Phase II trials expected in late 2008/early 2009
TAK-285 – EGFR/HER dual kinase - Demonstrated good target specificity, pharmacokinetics and distribution and efficacy in EGFR- and HER2-expressing xenograft models
TAK-593 -VEGF/PDGF – Preclinical data show potent pseudo-irreversibility against VEGF2 & PDGFbeta

]]> http://kinasecentral.wordpress.com/2008/10/23/millennium-present-data-on-kinase-programs-at-eortc-nci-aacr-meeting/feed/ 0 crimsoncanary EntreMeds Aurora A inhibitor ENMD-2076 effective in vivo http://kinasecentral.wordpress.com/2008/10/23/entremeds-aurora-a-inhibitor-enmd-2976-effective-in-vivo/ http://kinasecentral.wordpress.com/2008/10/23/entremeds-aurora-a-inhibitor-enmd-2976-effective-in-vivo/#comments Thu, 23 Oct 2008 17:40:12 +0000 crimsoncanary http://kinasecentral.wordpress.com/?p=774 ]]> Data presented at the EORTC-NCI-AACR Annual Meeting show EntreMed’ Aurora A kinase inhibitor ENMD-2076 to demonstrate strong antitumor effects in a xenograft model of human colon cancer.

]]> http://kinasecentral.wordpress.com/2008/10/23/entremeds-aurora-a-inhibitor-enmd-2976-effective-in-vivo/feed/ 0 crimsoncanary